TIL

Instil Bio, Inc. [TIL] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

TIL Stock Summary

Top 10 Correlated ETFs

TIL

Top 10 Correlated Stocks

TIL

In the News

TIL Financial details

Company Rating
-
Market Cap
70.86M
Income
-155.35M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
49
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-5.1
Forward P/E
-
PEG
1.66
P/S
-
P/B
4.28
P/C
-
P/FCF
-0.36
Quick Ratio
13.62
Current Ratio
14.53
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-23.89
EPS next Y
-
EPS next Q
-
EPS this Y
-30.35%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-80.81%
-
-
-
-
SMA20
-16.67%
SMA50
-31.82%
SMA100
-44.44%
Inst Own
-
Inst Trans
-
ROA
-58%
ROE
-65%
ROC
-0.62%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
6.08-14.0
52W High
-6.5%
52W Low
+118.17%
RSI
39
Rel Volume
9.94
Avg Volume
27.45K
Volume
272.75K
Perf Week
-20.62%
Perf Month
-34.12%
Perf Quarter
-50.53%
Perf Half Y
-62.91%
-
-
-
-
Beta
1.252
-
-
Volatility
3.52%, 2.47%
Prev Close
11.69%
Price
13.09
Change
10.09%

Something similar

Top by Market Cap
AAPL
DHR-PB
AMZ.DE
ABEC.DE
BRYN.DE
Top Correlated ETFs
FCA
IDNA
BKF
KEMQ
AADR
Top Correlated Stocks
603809.SS
002857.SZ
MHGVY
ING
SUZ
Similar Market Cap
PHR.LS
AFE.V
KGH.L
PXE
0858.HK

Company Profile

Healthcare Biotechnology
  • Volume Average 27.45K
  • Market Capitalization 70.86M
  • Employee 49
  • CEO Mr. Bronson Crouch
  • Headquarters Dallas,TX,US
  • IPO Date 2021-03-19
  • Website https://instilbio.com

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.